

Yaron Carmi

Department of Pathology, Sackler School of Medicine

Website: <https://www.carmilab.org/>



I completed my PhD studies summa cum laude at the Immunology Department in Ben-Gurion University of the Negev, studying how tumor-infiltrating myeloid cells interact with T cells and with the surrounding stroma, to promote tumor progression and escape. I made my postdoctoral work, at Stanford University, where I focused on understanding the key factors by which tumor-associated dendritic cells process molecules as foreign antigens. This work, which was published in *Nature* and *JCI* and *Cell* and was the basis for establishing a commercial company (Bolt therapeutics), which is on the verge of a phase-I clinical trial.

Over the last three years I have my own group at Tel-Aviv University where we study the processes and mechanisms through which tumor-reactive T cells are generated and licensed to act and how can we employ that knowledge to fight cancer. Recently, we describe a novel CD4⁺ T cell subset which express the high affinity Fc γ receptor and exert antibody-mediated cell cytotoxicity. This discovery provides a rational for a novel CAR design and the basis for the foundation of a commercial company (Gilboa therapeutics).